Trophoblast Extracellular Vesicles Rewire Immunity: A Symptom‐Relief Avenue for Recessive Dystrophic Epidermolysis Bullosa
Abstract
Redirecting immune responses toward tissue repair represents a promising strategy for treating inflammatory and degenerative diseases. Extracellular vesicles (EVs), derived from allogeneic stem cells, have shown potential for modulating proinflammatory immunity. Among these, placental-derived EVs (PEVs) are emerging as candidates for immune-mediated inflammatory disorders due to their role in establishing maternal immune tolerance. However, their applicability beyond pregnancy remains limited by key translational barriers, including the lack of a standardized and scalable source system and need to demonstrate immunomodulatory activity in non-pregnancy allogeneic contexts. In this study, we identify extravillous trophoblasts (EVTs), which play critical role in early placental development, as key source of immunoregulatory PEVs. To overcome donor variability, we employed the HIPEC cell model as established surrogate for primary EVTs and assessed the effects of their derived EVs (EVTEVs) on circulating monocytes, pivotal mediators of inflammatory responses. High-dimensional molecular profiling revealed that EVT-EVs, similar to EVs derived from first-trimester primary human trophoblast, carry a distinctive anti-inflammatory signature, including a unique miRNA repertoire enriched in immunoregulatory pathways. Integrated proteomic and lipidomic analyses demonstrated that EVT-EVs induce coordinated functional reprograming of monocytes toward an immunomodulatory, inflammation-resolving phenotype. Notably, EVT-EVs also modulated the inflammatory bias of monocytes from patients with recessive dystrophic epidermolysis bullosa (RDEB), a genetic disorder characterized by chronic inflammation, thereby promoting restoration of immune balance. Collectively, these findings identify EVT-EVs as a scalable, off-the-shelf platform with high translational potential for the treatment of chronic inflammatory diseases.
Related
- A Mechanistic Map of the Phenotypic Complexity in Recessive Dystrophic Epidermolysis Bullosa Provides Basis for Therapeutic Target Discovery and Drug Repurposing.
- HIF2α-Regulated Pathways Control Human Extravillous Trophoblast Functions by Modulating Cell-to-Cell Communication Through Extracellular Vesicles
- Synonymous COL7A1 c.6846G>C in Dystrophic Epidermolysis Bullosa: Oral Phenotypic Expansion and Palatal Ultrastructure
- ICAM-5: A marker for neuronally derived extracellular vesicles
- Mitochondrial and bioenergetic processes are enriched in large-but are reciprocally depleted in small extracellular vesicles
BibTeX
@article{hirt2026trophoblast,
title = {{Trophoblast Extracellular Vesicles Rewire Immunity: A Symptom‐Relief Avenue for Recessive Dystrophic Epidermolysis Bullosa}},
author = {Nell Hirt and Enzo Manchon and Ming Wu and Helene Le Buanec and Pauline Bataille and Emmanuelle Bourrat and Jean‐david Bouaziz and Nabila Jabrane‐ferrat and Reem Al-Daccak},
journal = {Journal of Extracellular Vesicles},
year = {2026},
month = sep,
doi = {10.1002/jev2.70315},
url = {https://hal.science/hal-05830174v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Trophoblast Extracellular Vesicles Rewire Immunity: A Symptom‐Relief Avenue for Recessive Dystrophic Epidermolysis Bullosa
AU - Nell Hirt
AU - Enzo Manchon
AU - Ming Wu
AU - Helene Le Buanec
AU - Pauline Bataille
AU - Emmanuelle Bourrat
AU - Jean‐david Bouaziz
AU - Nabila Jabrane‐ferrat
AU - Reem Al-Daccak
PY - 2026
DA - 2026/09/24
JO - Journal of Extracellular Vesicles
DO - 10.1002/jev2.70315
UR - https://hal.science/hal-05830174v1
AB - Redirecting immune responses toward tissue repair represents a promising strategy for treating inflammatory and degenerative diseases. Extracellular vesicles (EVs), derived from allogeneic stem cells, have shown potential for modulating proinflammatory immunity. Among these, placental-derived EVs (PEVs) are emerging as candidates for immune-mediated inflammatory disorders due to their role in establishing maternal immune tolerance. However, their applicability beyond pregnancy remains limited by key translational barriers, including the lack of a standardized and scalable source system and need to demonstrate immunomodulatory activity in non-pregnancy allogeneic contexts. In this study, we identify extravillous trophoblasts (EVTs), which play critical role in early placental development, as key source of immunoregulatory PEVs. To overcome donor variability, we employed the HIPEC cell model as established surrogate for primary EVTs and assessed the effects of their derived EVs (EVTEVs) on circulating monocytes, pivotal mediators of inflammatory responses. High-dimensional molecular profiling revealed that EVT-EVs, similar to EVs derived from first-trimester primary human trophoblast, carry a distinctive anti-inflammatory signature, including a unique miRNA repertoire enriched in immunoregulatory pathways. Integrated proteomic and lipidomic analyses demonstrated that EVT-EVs induce coordinated functional reprograming of monocytes toward an immunomodulatory, inflammation-resolving phenotype. Notably, EVT-EVs also modulated the inflammatory bias of monocytes from patients with recessive dystrophic epidermolysis bullosa (RDEB), a genetic disorder characterized by chronic inflammation, thereby promoting restoration of immune balance. Collectively, these findings identify EVT-EVs as a scalable, off-the-shelf platform with high translational potential for the treatment of chronic inflammatory diseases.
SN - 2001-3078
ER -